Protara Therapeutics (TARA) to Release Quarterly Earnings on Wednesday

Protara Therapeutics (NASDAQ:TARA - Get Free Report) is anticipated to issue its Q4 2024 quarterly earnings data before the market opens on Wednesday, March 12th. Analysts expect the company to announce earnings of ($0.57) per share for the quarter.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last announced its quarterly earnings results on Wednesday, March 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.09. On average, analysts expect Protara Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Protara Therapeutics Trading Up 2.6 %

Protara Therapeutics stock traded up $0.10 during trading on Friday, hitting $4.02. 188,072 shares of the company were exchanged, compared to its average volume of 317,690. The business's 50 day moving average is $4.56 and its 200 day moving average is $3.41. Protara Therapeutics has a 52 week low of $1.60 and a 52 week high of $10.48. The company has a market capitalization of $82.93 million, a P/E ratio of -1.43 and a beta of 1.69.

Wall Street Analysts Forecast Growth

TARA has been the subject of a number of recent analyst reports. HC Wainwright restated a "buy" rating and issued a $23.00 price objective on shares of Protara Therapeutics in a research note on Thursday. Guggenheim restated a "buy" rating and issued a $20.00 price objective on shares of Protara Therapeutics in a research note on Friday, December 6th.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.